Feitai capsule maakt dat patiënten hun chemokuur afmaken en verbetert significant controle - 20 procent - over de ziekte bij patiënten met niet-klein-cellige longkanker stadium IIIB en IV. copy 1

10 november 2013: Bron: Zhong Xi Yi Jie He Xue Bao. 2012 Jun;10(6):635-40

Feitai capsule maakt dat patiënten hun chemokuur afmaken en verbetert significant controle over de ziekte bij patiënten met niet-klein-cellige longkanker stadium IIIB en IV. Dit blijkt uit een gerandomiseerde studie bij totaal 60 patiënten.
Feitai capsule heeft al eerder bewezen een effectief aanvullend middel te kunnen zijn. Zie ook studie uit 2009: Effects of Feitai Capsule on quality of life in patients with advanced non-small-cell lung cancer: a randomized controlled trial, waarbij alleen Feitai capsule, dus zonder chemo of andere behandeling voor een significant betere kwaliteit van leven en ook langere levensduur zorgde. Misschein is dus chemo helemaal niet nodig?

Dit is het zoveelste bewijs dat zoals zoveel andere Chinese kruiden, deze een goed effect kunnen hebben al of niet aanvullend op chemo, bestraling, operaties enz. Zie onder TCM - Chinese kruiden voor meer artikelen.

Studieresultaten:
Totaal 60 patiënten met niet-klein-cellige longkanker, stadium IIIB / IV van de afdeling oncologie van het Fuzhou General Hosipital van Najing werden willekeurig ingedeeld in een behandelingsgroep ( n = 30 ) en een controlegroep ( n = 30). Patiënten in de behandelingsgroepen werden behandeld met vier cycli van chemotherapie plus Feitai capsule en patiënten in de controlegroep kregen alleen 4 cycli van chemotherapie.

Na elke chemokuur werden metingen verricht om te kijken of de behandeling aan zou slaan. De therapeutische werkzaamheid werd beoordeeld na 4 cycli.

96,42% van de patiënten uit de behandelingsgroep voltooiden de 4 x chemokuur plus Feitai capsule. 74,07% van de patiënten uit de controle groep voltooiden de 4 cycli van chemo. Uitstel van een volgende chemo bedroeg 3,57 % in de behandelingsgroep, terwijl dat van de controlegroep 14,8 % ( P = 0.007 0 ) bedroeg.
Het therapeutische effect, controle over de ziekte, bedroeg 78,6 % in de behandelingsgroep tegenover 59,3% ( P = 0.173 9 ) in de controlegroep.

Conclusie:
De onderzoekers concluderen dan ook dat Feitai Capsule het volgen van chemotherapie kan stimuleren bij patiënten met niet-klein-cellige longkanker stadium IIIB / IV.

Het volledige studierapport: Influence of Chinese herbal medicine Feitai Capsule on completion or delay of chemotherapy in patients with stage IIIB/IV non-small-cell lung cancer: a randomized controlled trial is gratis in te zien, maar alleen in het Chinees en niet vertaald.

Hier wel het abstract van deze studie in het engels met een referentielijst in het engels erbij:

Feitai Capsule can increase the chemotherapy completion rate in patients with stage ⅢB/Ⅳ NSCLC

Journal of Chinese Integrative Medicine: Volume 10, 2012 Issue 6

Influence of Chinese herbal medicine Feitai Capsule on completion or delay of chemotherapy in patients with stage ⅢB/Ⅳ non-small-cell lung cancer: a randomized controlled trial

1.	Shui-qiu Deng (Department of Disease Prevention, Fuzhou General Hospital of Nanjing Military Region, Fuzhou 350025, Fujian Province, China )
2.	Xue-nong Ouyang (Department of Oncology, Fuzhou General Hospital of Nanjing Military Region, Fuzhou 350025, Fujian Province, China E-mail: E-mail: oyxnong@163.com)
3.	Zong-yang Yu (Department of Oncology, Fuzhou General Hospital of Nanjing Military Region, Fuzhou 350025, Fujian Province, China )
4.	Xi-hu Dai (Department of Oncology, Fuzhou General Hospital of Nanjing Military Region, Fuzhou 350025, Fujian Province, China )
5.	Xi Chen (Department of Oncology, Fuzhou General Hospital of Nanjing Military Region, Fuzhou 350025, Fujian Province, China )
6.	Fang-zheng Fang (Department of Oncology, Fuzhou General Hospital of Nanjing Military Region, Fuzhou 350025, Fujian Province, China )
7.	Wen-wu Wang (Department of Oncology, Fuzhou General Hospital of Nanjing Military Region, Fuzhou 350025, Fujian Province, China )
8.	Zhi-zhen Liu (Department of Oncology, Fuzhou General Hospital of Nanjing Military Region, Fuzhou 350025, Fujian Province, China )

BACKGROUND: Chemotherapy completion rate can reflect the tolerance and compliance of patients to chemotherapy. Poor tolerance may result in delay or suspension of the comprehensive treatment plan, thus affect the efficacy of cancer treatment. Evaluating methods to improve the completion rate of chemotherapy and reduce the occurrence of delayed chemotherapy has gained increasing attention and is the significant area of study in the field of cancer treatment. Studies have shown that Chinese medicine combined with chemotherapy could improve the quality of life in patients with stage ⅢB/Ⅳ non-small-cell lung cancer (NSCLC).
OBJECTIVE: To observe the effects of Feitai Capsule, a Chinese patent herbal drug, combined with chemotherapy in patients with stage ⅢB/Ⅳ NSCLC.
DESIGN, SETTING, PARTICIPANTS AND INTERVENTIONS: A total of 60 diagnosed stage IIIB/IV NSCLC patients from the Department of Oncology, Fuzhou General Hosipital of Najing Military Region were randomly divided into treatment group (30 cases) and control group (30 cases). Patients in the treatment group were treated with chemotherapy plus Feitai Capsule and patients in the control group only received chemotherapy. Both groups of patients were treated for 4 therapeutic cycles.
MAIN OUTCOME MEASURES: The chemotherapy completion rate and the chemotherapy delay rate were observed in each cycle of treatment. The therapeutic efficacy was evaluated after 4 cycles.
RESULTS: The chemotherapy completion rate was 96.42% in the treatment group, while that of the control group was 74.07%. The chemotherapy delay rate was 3.57% in the treatment group, while that of the control group was 14.8% (P＝0.007 0). The disease control rate was 78.6% in the treatment group, while that of the control group was 59.3% (P＝0.173 9).
CONCLUSION: Feitai Capsule can increase the chemotherapy completion rate in patients with stage ⅢB/Ⅳ NSCLC.

Received September 27, 2011; accepted December 18, 2011; published online June 15, 2012.
Full-text LinkOut at PubMed. Journal title in PubMed: Zhong Xi Yi Jie He Xue Bao.

基金项目： “十一五”军队中医药重大临床攻关课题资助项目(No. 2006051002)
Correspondence: Xue-nong Ouyang, MD, Professor; Tel: 0591-83787037; E-mail: oyxnong@163.com

Full text of this article is in Chinese

References

1.	American Cancer Society. Cancer facts and figures 2006[M]. Atlanta: American Cancer Society, 2006. 13-14.

2.	Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ; American Cancer Society. Cancer statistics[J]. 2004; CA Cancer J Clin, 2004, 54(1) : 8-29.

3.	Lin LZ, Zhou DH, Zheng XT. Effect of traditional Chinese medicine in improving quality of life of patients with non-small cell lung cancer in late stage[J]. Zhongguo Zhong Xi Yi Jie He Za Zhi, 2006, 26(5) : 389-393. Chinese with abstract in English.

4.	Zhou YM, Piao BK, Hou W, Lin HS, Hua BJ, Xiong L, Zheng HG. Clinical observation of Feiliuping ointment on immune state and prognosis in patients with non-small-cell lung cancer[J]. Zhongguo Zhong Yi Yao Xin Xi Za Zhi, 2008, 15(5) : 78-79. Chinese.

5.	Liu JX. Effect of Chinese medicine in maintaining quality of life of cancer patients[J]. Zhonghua Zhong Liu Za Zhi, 2002, 24(3) : 309-310. Chinese.

6.	Ye L, Ouyang XN, Dai XH, Yu ZY, Liu ZZ. Clinical effect of Feitai Capsule in the treatment for 60 cases with advanced non-small cell lung cancer with the syndrome of deficiency of vital energy and phlegm blood-stasis[J]. Zhongguo Zhong Liu, 2010, 19(12) : 828-832. Chinese with abstract in English.

7.	Liu ZZ, Yu ZY, Ouyang XN, Dai XH, Chen X, Zhao ZQ, Wang WW, Li J, Tu H, Ye L, Yan Y. Effect of maintenance therapy with Feitai capsules in patients with advanced non-small cell lung cancer[J]. Lin Chuang Zhong Liu Xue Za Zhi, 2009, 14(4) : 344-346. Chinese with abstract in English.

8.	Han R. Cancer chemoprevention and drug treatment[M]. Beijing: Peking Union Medical College Press, 1995. 353-356. Chinese.
9.	DeVita VT, IIellman S Jr, Rosenberg SA. Cancer — Principles and practice of oncology. Translated by Xu CG, Zhang MH, Yang XJ. 5th ed[M]. Jinan: Shandong Science and Technology Press, 2002. 355. Chinese.
10.	Goldie JH, Goldman AJ. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate[J]. Cancer Treat Rep, 1979, 63(11-12) : 1727-1733.

11.	Wang RT, Shan BE, Li QX, Tang JF, Qiao F, Du XN, Li H, Ye J. Extracorporeal experimental study on immuno-modulatory activity of Astragalus membranaceus extract[J]. Zhongguo Zhong Xi Yi Jie He Za Zhi, 2002, 22(6) : 453-456. Chinese with abstract in English.

12.	Zhang S, Mou XY, Wang HM, Jiang SJ. Enhancement of the cytotoxic effect of cytokine induced killers by dendritic cells pulsed with Astragalus polysaccharides[J]. Zhongguo Mian Yi Xue Za Zhi, 2009, 25(2) : 140-142. Chinese with abstract in English.

13.	Hong G, Dai YH, Liu PX, Shen X, Wei YY, Li G. Advances in research on chemical constituents and pharmacological activities of Agrimonia pilosa[J]. Yao Xue Fu Wu Yu Yan Jiu, 2008, 8(5) : 362-363. Chinese with abstract in English.

14.	Ma LP, Zhao PR, Wang LX, Zhang SH. Inhibitory effects of Agrimonia pilosa Ledeb. water extract on Eca109 cells in vitro[J]. Zhengzhou Da Xue Xue Bao Yi Xue Ban, 2007, 42(1) : 149-151. Chinese with abstract in English.

15.	Wen Y, Bi L, Zhang YB, Chen WP. Inhibitory effects of Agrimonia pilosa Ledeb. water extract on lung cancer A549 cells in vitro[J]. Zhong Yi Yao Xin Xi, 2009, 26(5) : 33-35. Chinese.

16.	Wang F, Yuan ST, Zhu DN. Active components of antitumor fraction from Sarcandra glabra[J]. Zhongguo Tian Ran Yao Wu, 2007, 5(3) : 174-178. Chinese with abstract in English.
	[WANGFANG DATA]
17.	Kang M, Tang AZ, Liang G, Yi X, Liu J. A study on the inhibition of Sarcandrea extracts on proliferation of nasopharyngeal carcinoma cell[J]. Guangxi Yi Ke Da Xue Xue Bao, 2008, 25(3) : 347-349. Chinese with abstract in English.
	[WANGFANG DATA]